Anti-KCJ13/ KCNJ13/ KIR1.4 monoclonal antibody

Anti-KCJ13/ KCNJ13/ KIR1.4 antibody for FACS & in-vivo assay

Target products collectionGo to KCNJ13/KCNJ13 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0671-Ab-1/ GM-Tg-hg-MP0671-Ab-2Anti-Human KCNJ13 monoclonal antibodyHuman
GM-Tg-rg-MP0671-Ab-1/ GM-Tg-rg-MP0671-Ab-2Anti-Rat KCNJ13 monoclonal antibodyRat
GM-Tg-mg-MP0671-Ab-1/ GM-Tg-mg-MP0671-Ab-2Anti-Mouse KCNJ13 monoclonal antibodyMouse
GM-Tg-cynog-MP0671-Ab-1/ GM-Tg-cynog-MP0671-Ab-2Anti-Cynomolgus/ Rhesus macaque KCNJ13 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0671-Ab-1/ GM-Tg-felg-MP0671-Ab-2Anti-Feline KCNJ13 monoclonal antibodyFeline
GM-Tg-cang-MP0671-Ab-1/ GM-Tg-cang-MP0671-Ab-2Anti-Canine KCNJ13 monoclonal antibodyCanine
GM-Tg-bovg-MP0671-Ab-1/ GM-Tg-bovg-MP0671-Ab-2Anti-Bovine KCNJ13 monoclonal antibodyBovine
GM-Tg-equg-MP0671-Ab-1/ GM-Tg-equg-MP0671-Ab-2Anti-Equine KCNJ13 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0671-Ab-1/ GM-Tg-hg-MP0671-Ab-2; GM-Tg-rg-MP0671-Ab-1/ GM-Tg-rg-MP0671-Ab-2;
GM-Tg-mg-MP0671-Ab-1/ GM-Tg-mg-MP0671-Ab-2; GM-Tg-cynog-MP0671-Ab-1/ GM-Tg-cynog-MP0671-Ab-2;
GM-Tg-felg-MP0671-Ab-1/ GM-Tg-felg-MP0671-Ab-2; GM-Tg-cang-MP0671-Ab-1/ GM-Tg-cang-MP0671-Ab-2;
GM-Tg-bovg-MP0671-Ab-1/ GM-Tg-bovg-MP0671-Ab-2; GM-Tg-equg-MP0671-Ab-1/ GM-Tg-equg-MP0671-Ab-2
Products NameAnti-KCNJ13 monoclonal antibody
Formatmab
Target NameKCNJ13
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-KCNJ13 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species KCJ13/ KCNJ13/ KIR1.4 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0671
    Target NameKCNJ13
    Gene ID3769,100040591,94341,713741,477411,101099825,512288,100057299
    Gene Symbol and SynonymsKCNJ13,KIR1.4,KIR7.1,LCA16,SVD
    Uniprot AccessionO60928,O70617
    Uniprot Entry NameKCJ13_HUMAN,KCJ13_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000115474
    Target ClassificationN/A

    The target: KCNJ13, gene name: KCNJ13, also named as KIR1.4, KIR7.1, LCA16, SVD. This gene encodes a member of the inwardly rectifying potassium channel family of proteins. Members of this family form ion channel pores that allow potassium ions to pass into a cell. The encoded protein belongs to a subfamily of low signal channel conductance proteins that have a low dependence on potassium concentration. Mutations in this gene are associated with snowflake vitreoretinal degeneration. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Feb 2010].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.